ADVA
12.3.2020 09:02:07 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched a whole new way for communication service providers (CSPs) to drive more revenue from their already deployed fiber networks. With spectrum as a service , CSPs can now slice the optical spectrum in their fiber infrastructure, just like radio spectrum in 5G networks. They can then sell different frequency blocks to different customers, enabling them to fully harness the untapped value in their networks. Powered by ADVA’s FSP 3000 open line system (OLS), spectrum as a service is an entirely new approach for CSPs to utilize vast amounts of unused spectrum. By leveraging ADVA’s coherent optics, programmable flexgrid technology and intelligent network control, CSPs can start selling fully assured and differentiated optical spectrum services to their customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200312005038/en/
“Today we’re introducing a new way for CSPs to tackle skyrocketing data demand and diminishing margins. Optical spectrum in fiber networks can now be sliced and offered as differentiated services to multiple end users. This gives CSPs a completely fresh business case and a brand new area for revenue growth,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “Our unique open line system is the key to realizing the full benefits of the spectrum-as-a-service approach. Its spectrum gateway functionality and advanced optical layer control empower CSPs to elastically allocate optical spectrum to services and deliver virtually unlimited capacity. What’s more, with optical spectrum services, CSPs can put their end customers in control like never before.”
The ADVA FSP 3000 OLS provides the optimum platform for spectrum-as-a-service offerings. It creates an open and scalable optical layer ready to accommodate evolving demand and the latest innovation. With a modular design as well as multiple multiplexer and amplifier options, it's engineered to meet the specific requirements of modern metro, core and DCI applications. The ADVA FSP 3000 OLS removes the limits of the traditional fixed channel grid systems so that unused spectrum can be put to work. This approach also enables operators to take advantage of flexible resource utilization and future-proof their networks by avoiding unnecessary O/E/O conversions.
“Up until now, CSPs have been unable to monetize the vast amounts of unused spectrum in their networks. But thanks to advances in coherent optics, programmable flexgrid technology and intelligent network control, spectrum as a service is now a real and affordable option. CSPs can use the approach to unleash the full value of their fiber assets,” commented Jörg-Peter Elbers, SVP, advanced technology, ADVA. “Following multiple spectrum-as-a-service proof-of-concepts involving several partners and spanning different network domains, we're now removing the limits on fiber capacity for CSPs across the world. With this launch, we're unlocking the potential of today's fiber infrastructure and ushering in a new age of flexible, future-proof growth.”
Watch this video for more information on ADVA’s spectrum-as-a-service solution: https://youtu.be/FBCuuvYWN4A .
Further details are also available in these slides: https://adva.li/spectrum-as-a-service-slides .
Learn more about ADVA’s FSP 3000 open line system in this video: https://youtu.be/E_P8_ypxR1w .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200312005038/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release
Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom